FACULTY OF MEDICINE
Lund University

Medical Faculty

Department of Surgery, Clinical Sciences, Lund

Daniel Ansari, MD, PhD

September 18, 2016

The Editor-in-Chief – Lian-Sheng Ma
World Journal of Gastroenterology

Dear Editor,

Thank you for the constructive comments on our manuscript entitled "Immune Checkpoint Therapy for Pancreatic Cancer (Manuscript NO: 29003)". Enclosed is a revised version of our manuscript. All revisions in the text have been marked in red.

We have addressed all minor issues, and below please find a point-by-point reply to the points raised, indicating in detail our response. By that, we hope that our manuscript will be found suitable for publication in World Journal of Gastroenterology and we look forward to hearing your final decision.

Sincerely yours,

Daniel Ansari

Daniel Ansari, MD, PhD
Corresponding author

Reviewer 1

"This is a well written and up-to-date review of immune checkpoint therapy for pancreatic cancer. Relevant trials and articles are cited and discussed.

Postal address: Department of Surgery, Clinical Sciences Lund, Skåne University Hospital, SE-221 85 Lund, Sweden
Telephone Int. +46 46-222 46 72   *E-mail: daniel.ansari@med.lu.se*

Response: We appreciate the positive comment of reviewer 1.

There are a few comments/suggestions:

1. I would omit the exact search criteria in the abstract and leave it in the method section.

Response: This has been changed, and the abstract updated.

2. "Associated risk factors for PDA are: smoking, diabetes mellitus, he-redity, chronic pancreatitis, KRAS, TP53, SMAD4 and CDKNA2 muta-tions". I would not consider KRAS, TP53, SMAD4 and CDKNA2 muta-tions risk factors in this context.

Response: We agree with the reviewer. This section has been removed.

3. "PDA is classified as an exocrine cancer originating from the pancreat-ic ductal epithelium". That is rather doubtful; more likely it originates from acinar cells via acinar to ductal metaplasia (ADM), and PanIN pro-gression.

Response: We agree with the reviewer. This section has been removed, as this is beyond the scope of this article.

Reviewer 2

"Detailed review."

Response: We appreciate the positive comment of reviewer 2.